ExpreS[2]ion will apply its clinically validated Drosophila S2 insect cell expression system, ExpreS[2], to produce 2019-nCoV viral antigens in the company’s clinically validated cell lines, as well as in ExpreS[2]ion’s new HighMan-S2™ immunogenicity-enhancing cell line. The aim is to produce the vaccine antigens and test these in mice to demonstrate immunogenicity, and through collaborations demonstrate efficacy in in vitro or animal models as these become available. The Wuhan Coronavirus vaccine program (“ExpreS[2]-CoV”)’s first stage has a timeline of two-three months and is contained within ExpreS[2]ion’s existing budget. In the second stage, which is expected to take place in H2 2020, available animal models will be implemented for in vivo efficacy testing of ExpreS[2]-CoV. ExpreS[2]ion will continuously seek infectious diseases vaccine development partnering opportunities in academia and the biopharmaceutical industry for initiation of the third stage, clinical investigations. CEO Bent Frandsen comments “ExpreS[2]ion’s ExpreS[2] system is currently employed in five Malaria vaccine clinical programs, with the Rh5 program having been successfully tested in a Phase IIa malaria challenge study by the University of Oxford. These results demonstrate the wide applicability of our system to produce complex vaccine antigens to address critical unmet medical needs. Our aim now is to contribute to the fight against the Wuhan Coronavirus in any way we can, first step being to produce ExpreS[2]-CoV.” About the Wuhan Coronavirus: A novel Coronavirus (2019-nCoV) outbreak was reported in Wuhan, China in late December 2019. The 2019-nCoV Coronavirus is a part of the same family as SARS and MERS, and there have been more than 20 000 confirmed cases and over 400 deaths as of February 4[th,] 2020. The latest situation updates are available on the WHO web page: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Certified Adviser Svensk Kapitalmarknadsgranskning AB Telefon: +46 11 32 30 732 E-post: ca@skmg.se